Quarterly ResultAug 7, 2026, 08:07 AM
Alps Group Inc Revenue Grew 44% to $4.9M; Began Trading on Nasdaq
AI Summary
Alps Group Inc reported its financial results for the fiscal year ended March 31, 2026, with revenue growing 44% to $4.9 million, driven by cellular therapy, medical testing, and healthcare products. The company's net loss improved to $2.1 million from $2.6 million year-over-year. Fiscal year 2026 was transformational, marked by its Nasdaq Global Market listing in October 2025, significant advancements in its cellular therapy pipeline, and strategic leadership appointments.
Key Highlights
- Revenue increased 44% to $4.9 million for the year ended March 31, 2026.
- Net loss for the year was $2.1 million, down from $2.6 million in the prior year.
- Gross profit rose to $1.6 million, up from $1.3 million in the previous year.
- Began trading on the Nasdaq Global Market under ticker "ALPS" in October 2025.
- Appointed Cheing Lye-Ping (Penny) as Chief Financial Officer.
- Advanced Natural Killer (NK) Cell Therapy program, MyImmune, to process validation.
- Expanded MyGenome Sdn. Bhd.'s laboratory accreditation to include Whole Genome Sequencing.
- Appointed Lee Hee Hang, former Ernst & Young Partner, to the Board of Directors.
Price Impact
More from ALPS